Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 1
1989 5
1990 8
1991 1
1992 4
1993 2
1994 1
1995 4
1996 3
1997 4
1998 4
1999 2
2001 3
2002 6
2003 2
2004 3
2005 3
2006 4
2007 4
2008 7
2009 5
2010 5
2011 13
2012 8
2013 3
2014 5
2015 7
2016 2
2017 3
2018 3
2019 1
2020 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

117 results

Results by year

Filters applied: . Clear all
Page 1
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators. Fizazi K, et al. N Engl J Med. 2019 Mar 28;380(13):1235-1246. doi: 10.1056/NEJMoa1815671. Epub 2019 Feb 14. N Engl J Med. 2019. PMID: 30763142 Clinical Trial.
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Petrenciuc O, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators. Fizazi K, et al. N Engl J Med. 2020 Sep 10;383(11):1040-1049. doi: 10.1056/NEJMoa2001342. N Engl J Med. 2020. PMID: 32905676 Clinical Trial.
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators. Ryan CJ, et al. N Engl J Med. 2013 Jan 10;368(2):138-48. doi: 10.1056/NEJMoa1209096. Epub 2012 Dec 10. N Engl J Med. 2013. PMID: 23228172 Free PMC article. Clinical Trial.
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE; COU-AA-302 Investigators. Ryan CJ, et al. Lancet Oncol. 2015 Feb;16(2):152-60. doi: 10.1016/S1470-2045(14)71205-7. Epub 2015 Jan 16. Lancet Oncol. 2015. PMID: 25601341 Clinical Trial.
Candida nivariensis: Identification strategy in mycological laboratories.
Cartier N, Chesnay A, N'diaye D, Thorey C, Ferreira M, Haillot O, Bailly É, Desoubeaux G. Cartier N, et al. Among authors: haillot o. J Mycol Med. 2020 Dec;30(4):101042. doi: 10.1016/j.mycmed.2020.101042. Epub 2020 Aug 28. J Mycol Med. 2020. PMID: 32919860 Review.
[Medicoeconomic aspects of benign prostatic hyperplasia medical treatment].
Lebdai S, Azzouzi AR, Delongchamps NB, Benchikh A, Campeggi A, Cornu JN, Dumonceau O, Faix A, Fourmarier M, Haillot O, Lukacs B, Mathieu R, Misrai V, Robert G, de La Taille A, Descazeaud A. Lebdai S, et al. Among authors: haillot o. Prog Urol. 2016 Feb;26(2):129-36. doi: 10.1016/j.purol.2015.10.010. Epub 2015 Nov 28. Prog Urol. 2016. PMID: 26643518 Review. French.
Eliciting men's preferences for decision-making relative to treatments of localized prostate cancer with a good or moderate prognosis.
Lejeune C, Bourredjem A, Binquet C, Cussenot O, Boudrant G, Papillon F, Bruyère F, Haillot O, Koutlidis N, Bassard S, Fournier G, Valeri A, Moreau JL, Pierfitte B, Moulin M, Berchi C, Cormier L. Lejeune C, et al. Among authors: haillot o. World J Urol. 2023 Jun;41(6):1541-1549. doi: 10.1007/s00345-023-04416-w. Epub 2023 May 12. World J Urol. 2023. PMID: 37173454 Review.
Laser treatment of benign prostatic hyperplasia in patients on oral anticoagulant therapy: a review.
Descazeaud A, Robert G, Azzousi AR, Ballereau C, Lukacs B, Haillot O, Dumonceau O, Devonec M, Fourmarier M, Saussine C, de la Taille A; Committee for lower urinary tract symptoms of the French Association of Urology. Descazeaud A, et al. Among authors: haillot o. BJU Int. 2009 May;103(9):1162-5. doi: 10.1111/j.1464-410X.2008.08284.x. Epub 2009 Dec 22. BJU Int. 2009. PMID: 19154457 Review.
117 results